Please login to the form below

Not currently logged in
Email:
Password:

Vifor

This page shows the latest Vifor news and features for those working in and with pharma, biotech and healthcare.

Real-world data finds patients feel better on Entresto, says Novartis

Real-world data finds patients feel better on Entresto, says Novartis

Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

Latest news

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of the Atlantic. ... That left AZ playing catch-up in the market with Vifor’s Veltassa (patiromer),

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since 2015. ... delaying approval and giving Vifor time to consolidate its position in the market.

  • Novartis and Bayer among backers for European big data project Novartis and Bayer among backers for European big data project

    Novartis, Bayer, Servier and Vifor Pharma are among those participating in BigData@Heart, a five-year, 19m project supported by the Innovative Medicines Initiative (IMI).

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    Vifor wins European approval for Veltassa. European Commission approves the drug to treat hyperkalaemia. ... The European Commission (EC) has approved Vifor’s Veltassa (patiromer) to treat adults with hyperkalaemia, a potentially life threatening

  • Pfizer gets FDA panel recommendation for biosimilar EPO Pfizer gets FDA panel recommendation for biosimilar EPO

    If approved it will also be sold by Vifor Pharma in the US dialysis market. ... Epogen shrank by a third last year thanks in part to switching of some patients to Amgen's long-acting ESA Aranesp (darbepoetin alfa) and competition from Roche/Vifor's

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Under the original licence Vifor's rights covered Europe, Canada, Mexico, Central and South America and South Korea. ... In return for the expanded territory, Vifor is paying ChemoCentryx $20m upfront and tiered double digit royalties on potential net

  • Deal Watch July 2016 Deal Watch July 2016

    Galenica, the Swiss healthcare company that is preparing itself for a split into two parts, Vifor Pharma (healthcare product development, manufacturing and marketing) and pharmacy and wholesaler service provider, has acquired ... The Vifor division,

  • Deal Watch May 2016 Deal Watch May 2016

    The presence of the CRL on the books however did not deter Vifor Fresenius Medical Care Renal Pharma's decision to license Rayaldee [a vitamin D prohormone treatment] from OPKO paying ... 293. OPKO Health/ Vifor Fresenius. Licence. Rayaldee in EP, CA,

  • Pharma deals in August 2015 Pharma deals in August 2015

    Collaboration. 219. Relypsa. Vifor Fresenius. Patiromer oral suspension in treating hyperkalemia.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Hansa Medical poaches Vifor Pharma’ s CEO. Søren Tulstrup becomes the Swedish biopharma’s CEO and president. ... Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global

  • Swiss biotech Inositec appoints new chief medical officer Swiss biotech Inositec appoints new chief medical officer

    Dr van Alphen joins from Roche, where he headed its operational excellence team and prior to this he was chief medical officer at Vifor Pharma, head of medical affairs Europe at

  • Galenica Group strengthens management team Galenica Group strengthens management team

    Stefan Schulze has been appointed as chief operating officer and president of the executive committee of Vifor Pharma, part of the Switzerland-based Galenica Group. ... We opted for these variant because of the excellent knowledge Stefan Schulze brings

  • Lupin appoints Thierry Volle president for EMEA Lupin appoints Thierry Volle president for EMEA

    Lupin appoints Thierry Volle president for EMEA. He moves to the company from Vifor. ... He joins the firm from Vifor Pharma, where he was the head of EU and International business operations, and prior to that he served at Wyeth.

  • Verona names David Ebsworth as non-executive chairman Verona names David Ebsworth as non-executive chairman

    Verona names David Ebsworth as non-executive chairman. He joins from Vifor Pharma. ... He most recently served as CEO at Vifor Pharma and was also named CEO of Galenica in 2011, continuing to be an adviser for both firms.

More from appointments
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics